Clinical Trials

Study Title

Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects with Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies.

Purpose

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)

For more information visit
https://clinicaltrials.gov/study/NCT06880744

Interested in Volunteering for the Study?
If you would like more information about this study, please call us at (318) 212-8671

Eligibility

Study Process